Phillip Md Et Al Frost Buys 150,000 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 150,000 shares of the company’s stock in a transaction that occurred on Friday, January 17th. The shares were acquired at an average cost of $1.47 per share, for a total transaction of $220,500.00. Following the acquisition, the chief executive officer now directly owns 213,186,477 shares of the company’s stock, valued at $313,384,121.19. This trade represents a 0.07 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Wednesday, January 15th, Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock. The shares were bought at an average cost of $1.48 per share, for a total transaction of $740,000.00.
• On Friday, December 13th, Phillip Md Et Al Frost acquired 125,000 shares of OPKO Health stock. The stock was bought at an average price of $1.59 per share, with a total value of $198,750.00.
• On Wednesday, December 11th, Phillip Md Et Al Frost bought 500,000 shares of OPKO Health stock. The shares were bought at an average price of $1.56 per share, for a total transaction of $780,000.00.
• On Friday, November 29th, Phillip Md Et Al Frost purchased 199,072 shares of OPKO Health stock. The shares were bought at an average price of $1.53 per share, with a total value of $304,580.16.
• On Friday, November 22nd, Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock. The stock was purchased at an average cost of $1.59 per share, with a total value of $159,000.00.
• On Thursday, November 14th, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.62 per share, for a total transaction of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost purchased 280,183 shares of OPKO Health stock. The stock was purchased at an average price of $1.50 per share, with a total value of $420,274.50.

OPKO Health Price Performance

OPKO Health stock opened at $1.47 on Friday. The firm’s 50-day moving average is $1.54 and its two-hundred day moving average is $1.51. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. The stock has a market capitalization of $1.00 billion, a P/E ratio of -7.74 and a beta of 1.63. OPKO Health, Inc. has a 12-month low of $0.86 and a 12-month high of $1.76.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. StockNews.com downgraded shares of OPKO Health from a “hold” rating to a “sell” rating in a report on Wednesday. HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a research report on Wednesday, January 8th. Finally, Barrington Research reiterated an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a report on Friday, November 8th.

Institutional Trading of OPKO Health

Several hedge funds and other institutional investors have recently bought and sold shares of the company. FMR LLC lifted its stake in shares of OPKO Health by 103.6% during the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 11,089 shares during the period. Algert Global LLC acquired a new stake in OPKO Health in the 2nd quarter worth about $44,000. Orion Portfolio Solutions LLC acquired a new stake in OPKO Health in the 3rd quarter worth about $45,000. Private Advisor Group LLC increased its stake in shares of OPKO Health by 242.7% during the 3rd quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock valued at $53,000 after acquiring an additional 25,000 shares during the last quarter. Finally, World Investment Advisors LLC acquired a new position in shares of OPKO Health during the 3rd quarter valued at about $61,000. 64.63% of the stock is owned by hedge funds and other institutional investors.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.